Overview
AI-enabled antibody discovery for therapeutic development.
Details
AbCellera (Nasdaq: ABCL) discovers therapeutic antibodies using high-throughput microfluidics and ML. Partnerships with Lilly (incl. bamlanivimab), Pfizer, and Regeneron.
AbCellera
AI-enabled antibody discovery for therapeutic development. AbCellera (Nasdaq: ABCL) discovers therapeutic antibodies using high-throughput microfluidics and ML. Partnerships with Lilly (incl. bamlanivimab), Pfizer, and Regeneron.